Breaking News

Ligand Earns SAGE Milestone

May 12, 2014

SAGE-547 enters clinical development

Ligand Pharmaceuticals Inc. has earned a $150,000 milestone payment from SAGE Therapeutics (SAGE) related to the initiation of a Phase 1/2 trial of SAGE-547 for the treatment of super-refractory status epilepticus (SRSE), a life-threatening seizure condition.
SAGE-547 is an intravenous agent that utilizes Ligand’s Captisol technology. Ligand and SAGE entered a platform license agreement in 2013 for the development and commercialization of Captisol-enabled therapeutics for a broad range of debilitating central nervous system conditions. The companies recently expanded the agreement to cover additional therapy areas for certain compounds.
“SAGE is a biopharmaceutical company committed to developing and commercializing novel medicines to treat life-threatening, rare central nervous system disorders. SAGE-547 is their lead product candidate. We commend the SAGE team on their progress with this important new therapy and also congratulate them on their recent receipt of U.S. Orphan Drug Designation for SAGE-547 for the treatment of SE,” said John Higgins, president and chief executive officer of Ligand.
“The treatment options for status epilepticus, a life-threatening disease, are inherently limited and there are no specifically approved therapies for SRSE. Our partnership with SAGE is but one example of Ligand’s science and technologies being utilized under licensing agreements to develop or improve treatments across a variety of medical conditions,” added Mr. Higgins.

blog comments powered by Disqus
  • Cold Chain Packaging Trends

    Cold Chain Packaging Trends

    Kristin Brooks, Contract Pharma||February 4, 2016
    Susan Li of UPS discusses supply chain trends, challenges, and packaging innovations

  • Packaging Equipment Trends Preview

    Packaging Equipment Trends Preview

    Kristin Brooks, Contract Pharma||January 26, 2016
    Christian Treitel of Bosch Packaging Technology discusses trends and capabilities

  • Filings Update

    Filings Update

    December 1, 2015
    Roche, Pfizer, Janssen, BMS and more

  • CMC Biologics: Growing Through Innovation

    Tim Wright, Editor||January 28, 2016
    The new chief exec talks about industry trends and growth plans.

  • Cold-Chain Logistics & The Central Lab

    Kristin Brooks, Associate Editor||January 28, 2016
    Eric Hayashi of LabConnect discusses safety measures to ensure sample integrity

  • A Look at DCAT Week ‘16

    Tim Wright, Editor||January 28, 2016
    On the pulse of the pharmaceutical manufacturing value chain, DCAT Week ‘16 will deliver top-flight education programs and networking events.